The positive benefit-risk profile of vericiguat in its approved indication in patients with HFrEF following a recent heart failure event based on the pivotal Phase III VICTORIA trial remains unchanged
Vivo Bio Tech will have end-to-end responsibility for conducting the full spectrum of pre-clinical safety and regulatory studies
Quest will now offer dialysis-related clinical testing services to independent dialysis clinics
The INSPIRE-1 and INSPIRE-2 trials are Phase 3 studies assessing the efficacy and safety of tildrakizumab 100 mg (ILUMYA) in adults with active psoriatic arthritis (PsA)
There is a significant unmet medical need for antidepressants that are effective, rapid onset of action and to be well tolerated
ARGX-119 is the sixth molecule developed through our Immunology Innovation Program to show proof-of-concept
The decision to advance subcutaneous and oral amycretin into phase 3 is based on feedback received from regulatory authorities
The newly launched protocol will accelerate the clinical development of stenoparib and its drug-specific Drug Response Predictor (DRP) companion diagnostic (CDx) toward potential FDA approval
Subscribe To Our Newsletter & Stay Updated
